Hematologic Malignancies – Selinexor

Area of TherapyPhase IPhase IIPhase III
Multiple Myeloma (penta-refractory) | STORM

Rights : XPOVIO (selinexor) is approved in the U.S. in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

Approved
Multiple Myeloma (relapsed/refractory) | BOSTON
Phase I
Phase II
Phase III
Multiple Myeloma (relapsed/refractory and front-line) | STOMP
Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma DLBCL (relapsed/refractory) | SADAL

Rights : sNDA Submitted Dec 23, 2019 requesting accelerated approval.

Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma (combination with rituximab-gemcitabine-dexamethasone-platinum (R-GDP)) | XPORT-DLBCL-030

Rights : Expected to start in 2020.

Phase I
Phase II
Phase III
Diffuse Large B-cell Lymphoma (combination with chemo and non-chemo regimens) | XPORT-DLBCL-025

Rights : Expected to start in 2020.

Phase I
Phase II
Phase III

Solid Tumor Malignancies – Selinexor

Area of TherapyPhase IPhase IIPhase III
Liposarcoma (advanced unresectable dedifferentiated liposarcoma) | SEAL
Phase I
Phase II
Phase III
Endometrial Cancer | SIENDO
Phase I
Phase II
Phase III
CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027

Rights : Expected to start in 2020.

Phase I
Phase II
Phase III

Glioblastoma Multiforme (GBM) – Selinexor

Area of TherapyPhase IPhase IIPhase III
Glioblastoma | KING
Phase I
Phase II
Phase III
Glioblastoma (combination with active agents / newly diagnosed or recurrent) | XPORT-GBM-029

Rights : Expected to start in 2020.

Phase I
Phase II
Phase III

Additional Oncology Programs – Eltanexor and KPT-9274

Area of TherapyPhase IPhase IIPhase III
Myelodysplastic Syndromes (MDS)(single agent or in combination with hypomethylating agents)

Rights : Drug: eltanexor. Combination study expected to start in 2020.

Phase I
Phase II
Phase III
Colorectal Cancer (CRC) and Prostate Cancer (PrC)

Rights : Drug: Eltanexor

Phase I
Phase II
Phase III
Solid Tumors & AML

Rights : Drug: KPT-9274

Phase I
Phase II
Phase III

Other Indications

Area of TherapyPhase IPhase IIPhase III
Lymphoma in Companion Animals

Rights : Drug: verdinexor

Phase I
Phase II
Phase III

Partnerships

Ono licensed rights to selinexor and eltanexor in the following territories: Japan, S. Korea, Taiwan, Hong Kong, and ASEAN Countries 


antegene-logo

Antegene licensed rights to selinexor and eltanexor in China and Macau

Antengene licensed rights to KPT-9274 and verdinexor in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries


Anivive holds exclusive worldwide rights to research, develop, and commercialize verdinexor only for the treatment of cancer in companion animals